Speakers

Nikola Baker-Munton

Nikola Baker-Munton

Nicola Baker-Munton is the founder and Chief Executive Officer of Stratagem Intellectual Property Management Limited. Nicola started her career in business qualifying as a UK Patent Agent and European Patent Attorney at The Wellcome Foundation Limited, having gained a joint honours degree in biology and biochemistry. During her nine years as an industrial practitioner at Wellcome, Nicola recognised the need for much greater assistance with commercial intellectual property management in the private sector, in particular for SMEs and academic institutions helping them to protect and commercialise their science. Working in the private sector from 1995, Nicola founded Stratagem IPM in 1999, and has gained considerable experience of actively and strategically managing intellectual property portfolios from inception through development to market, and from academia through startup to stock market listing. The success of the holistic approach to strategic IP management led to the creation of Stratagem Corporate Finance & Strategy Ltd in 2001 which helps with seed funding, re-financing and the financial re-structuring of companies. Building on her considerable experience in negotiation, in 2007 Nicola qualified as an accredited mediator providing further skills for dispute resolution in the IP and general corporate arenas.


Michał Bańka

Michał Bańka

Michał Bańka worked at the Ministry of Economy to manage and mediate implementation of several EU funded programs. Since 2006 his responsibilities have included running the financial departments of three Programs: (1) Improving the Competitiveness of Enterprises, (2) Innovative Economy and (3) Infrastructure and Environment. He has held the positions of Deputy Director, and from 2012 Director of the Department of Business Environment Institution Support of the Polish Agency for Enterprise Development. His responsibilities include: (1) Providing support for business incubators in finding innovative ideas and capital input for “Start-ups”, (2) Support of the ‘Business Angels’ Network, (3) Support for Business Environment Institutions, (4)

Originator, Loan fund managers for micro and small enterprises with the participation of business angel or venture capital fund.

Financing of advisory services that are necessary to attract external investors. His business career is combined with an academic role involving teaching at the Faculty of Political Science at Warsaw University. He is the project manager and general executive of R & D projects of the Ministry of Science and Higher Education and author and co-author of several monographs and scientific articles.


Jacek Brol

Jacek Brol

Marketing Manager at BASF Polska Sp. o.o.

Result driven marketing professional with diverse international background. Has about 18 years of experience within Agri business in various marketing roles concentrating on market approach strategies, team and people development with a focus on customers. Proved his leadership skills by effectively driving and implementing complex multi-functional team projects. He started his carrier at BASF in sales, and after six years spent on close collaboration with farm(s) moved onto marketing. He has gained international experience being responsible for product launches in Central European countries. Has broad experience in:

- Expertise in agchem industry

- Analysis of value chains, market trends and market forecast

- Portfolio- und Product Lifecycle Management

- Leading cross functional, multicultural project teams

- Development of pricing strategies

- Strategy development and implementation

Jacek Brol graduated from Wroclaw University of Environmental and Life Sciences with a degree in Agriculture.


Clarie Brown

Clarie Brown

Claire Brown, PhD, MBA. Claire Brown is currently an Investment Manager for a Life Science focused Seed fund based out of Manchester, UK. Prior to this she was a Project Director at Astrazeneca responsible for the delivery of strategic cross therapy scientific initiatives, identifying & securing innovative investment opportunities for AZ-Medimmune and in-licensing & repositioning internal assets.

She has over 15 years experience working within the Biopharmaceutical industry managing projects across a variety of therapy areas and multiple stages of development including life cycle management. Prior to Astrazeneca Claire held a variety of Scientific focused roles in the U.S. at UCB and Genzyme, gaining experience across a variety of modalities (incl. cell therapy, recombinant proteins, and devices) and areas of research (inc. orphan diseases)

Educated in Scotland Claire first received her BSc (Hons) from the University of Glasgow, subsequently followed by a PhD and more recently an MBA.


Adam Cudny

Adam Cudny

Adam Cudny President of the Board, CEO, Investment Committee

Financial expert with over 20 year-experience. Completed 3 independent finance faculties: Masters’ Degree in Economy at PWSBiA Warsaw and two other finance-related in London (CIMA and ACCA). Since 1996 he has been connected with international finance (6 years in PwC, 15 years in Trio Management, Hexa Group), ownership supervision (7 years in Relyonart VC Fund) and fund-raising for start-ups in IT sector and professional services. Board Member of >10 companies, created >50 start-ups, with total asset value under active management of > PLN 50M, appraised and carried out ca. 30 transactions in Poland and abroad valued >PLN 1B.


Gareth Davies

Gareth Davies

Gareth is an agrotech entrepreneur based in Cambridge, UK. His company, Yagro, is an internet platform which allows farmers to benchmark and purchase agricultural input prices (seeds, fertilizer, chemicals). Yagro is currently in its seed funding round.

Before launching Yagro, Gareth worked for the global agribusiness giant Syngenta in Basel, Switzerland. His roles included running an incubator for new business models, launching a new venture capital portfolio focused on emerging markets, and developing derivatives-based risk management products for farmers. He held a Board appointment in a portfolio company and spoken regularly at industry conferences on behalf of Syngenta.

Gareth began his career as a management consultant in the London office of a boutique strategy firm, and has worked in West Africa with the peer-to-peer microfinance lending platform, Kiva.org.

He holds a First Class Honours Masters degree in Chemistry from Oxford University, and an MBA from the London Business School.


Sander van Deventer

Sander van Deventer

Sander van Deventer is a founder and managing partner of Forbion Capital Partners. He serves as a non-executive on the boards of Argos Therapeutics, Inc., giCare Inc., Hookipa AG, uniQure NV and enGene, Inc. He also is a professor in Transla-tional Gastroenterology at the University of Leiden and an accomplished scientist: He authored more 400 peer-review scientific papers and supervised more than 40 PhD students. Sander van Deventer - a certified internist and gastroenterologist - received his medical degree and doctorate (of philosophy) from the University of Amsterdam, after defending a thesis on the biological activities of bacterial lipopolysaccharides in humans. Following board certification in internal medicine and gastroenterology he worked as a scientist in the Laboratory for Medical Biochemistry, Rockefeller University, New York. He was the first to adminis-ter an anti - TNF monoclonal antibody (later registered as Remicade®) to patients with Crohn’s disease, the first to infuse apolipoproteinA1 in humans and had a critical role in the development of other therapeutic interventions, targeting cytokines, cytokine receptors, T-cells and signal transduction pathways, using small molecules, antibodies, peptides, proteins and anti-sense DNA technologies. He supervised the development of Glybera, the first gene therapy product to be approved in Europe, and several other gene therapy products. In 1995, he became director of the laboratory for Experimental Internal Medicine at the Academic Medical Center in Amsterdam, and continued to work on therapeutic signal transduction inhibition, gene thera-pies, and (genetically engineered) probiotics. From 2001 until 2004, he chaired the Department of Gastroenterology and Hepa-tology at the Academic Medical Center in Amsterdam. In 1998 he co-founded Amsterdam Molecular Therapeutics (AMT N.V.) currently uniQure B.V., developing AAV-based gene therapy products and now listed on Nasdaq, acting subsequently as CSO, CMO and CEO.


Kinga Drechny

Kinga Drechny

Kinga has a Master’s degree in Administration with a specialization in Public Relations from the Jagiellonian University in Krakow, Poland. Earlier in her career Kinga worked for the Regional Government and managed both promotion and implementation of the region’s tourist agenda. More recently she worked as the Marketing Director for Krakow Airport where she was responsible for promotion of the airports activities and presence regionally and internationally. Presently Kinga holds the post of Marketing Director for the Jagiellonian University - Poland’s most prestigious educational institution - where she is responsible for synthesis and implementation of the University’s, communication, marketing and PR strategy.

Kinga also works with LSBC assisting with marketing and business development.


Jonathan Gee

Jonathan Gee

Dr Jonathan Gee Investment Director SPARK Venture Management Ltd and SPARK Impact Ltd

Dr Gee is responsible for SPARK Venture Management’s healthcare and life sciences investment activities. He holds an investment management certificate and has over fifteen years experience working with IP driven, high growth technology companies as an investor and board member. He is co-chairman of the Investment Committee of the NorthWest Fund for BioMedical, a regional development (JEREMII) fund supported by ERDF and EIB. His investment focus covers all healthcare from drug discovery to medical software, devices and diagnostics. Investments he is or was responsible for include Adaptimmune, a cancer therapy company which IPO’d in April 2015 with a market cap on NASDAQ of $820m, Natural Motion, a mobile gaming company acquired by Zynga Inc for over $500m in February 2014, Oxford Immunotec, TB diagnostics company which floated on NASDAQ in November 2013, Vivacta Ltd, a point of care diagnostics business sold to Novartis for $90m in December 2012, and GlycArt Biotechnology, acquired by Roche for over £100m in July 2005. As Chief Executive of Imperial College Innovations from 1997 to 2001, he was responsible for spinning out over 30 new University start up companies. He established the first technology seed fund at Imperial College and ran this for its first two years. He gained his management training in Unilever, and has a background in marketing in the medical diagnostics industry where he was International Product Group Manager at Unilever’s successful OTC pregnancy testing company, Unipath. He holds a D Phil in cancer research from Oxford University, and was awarded BSc in Cellular Pathology with first class honours by Bristol University.


Leszek Grabarczyk

Leszek Grabarczyk

Leszek Grabarczyk, Deputy Director, National Centre for Research and Development (NCBR)

Since 2011, Leszek Grabarczyk has been Deputy Director of the National Centre for Research and Development (NCBR) – a government agency with an annual budget of PLN 5.5bn which supports the R&D sector in Poland. He is responsible for the development and implementation of programmes that promote innovation and research commercialisation. In 2014, the NCBR has launched BRIdge – a family of programmes that constitute Poland’s first ever system of financing new technologies by the public-private partnership while using private equity funds together with the world’s largest entities of this type. Thanks to the activities of the NCBR, Poland’s R&D expenditure in 2012 achieved a record result of PLN14.4 billion – almost 23% more than in the previous year.


Patric Gresko

Patric Gresko

Patric Gresko is Head of Unit in EIF’s Venture Capital team. EIF is the largest European venture capital fund-of-funds with more than EUR 3bn under management and a portfolio of over 220 venture capital funds.

Patric leads a team that invests in early stage funds and manages a portfolio of venture capital funds representing total commitments of more than EUR1bn in all major technology sectors. With EIF’s Venture Capital team, he is further developing EIF’s activity by designing and implementing new innovative equity products, notably in the impact investing and corporate venturing spaces.

He started his career with PricewaterhouseCoopers in Luxembourg as an auditor and consultant for the financial sector. He holds an MSc in Business Engineering from HEC Management School – University of Liège.


Andrew Harrison
 

Andrew Harrison

Andrew Harrison Chief Regulatory Affairs Officer & General Counsel Andrew serves as both Chief Regulatory Affairs Officer and General Counsel, bringing over 14 years of extensive experience in technical quality assurance, compliance, regulatory affairs and government affairs/public policy. He taps into his legal training to analyze and address key situations impacting FDA-regulated companies. Andrew is a welcome resource to our clients in need of strong domain support on regulatory approvals or clearances, clinical trials, advertising & promotion, good manufacturing practices, post-approval requirements, recalls or market withdrawals, audits, inspections, warning letters and enforcement actions such as injunctions and consent decrees. He can be reached at a.harrison(at)rcainc.com.


Krzysztof Jakubczak

Krzysztof Jakubczak

Krzysztof Jakubczak is a graduate from the Institute of Optoelectronics of the Military University of Technology, Warsaw, Poland. He achieved his PhD in the technical sciences from the Czech Technical University in Prague. His technical background is in military technologies, lasers, optics (classical, X-ray and EUV), infrared technology, light modulation and detection, secondary sources for nanolithography, vacuum systems and spectroscopy. Krzysztof is an experienced R&D engineer. As Deputy Project Manager he worked on design of HiLASE laser research center and establishment of cooperation with the parties. He led the R&D team as a Research Program Leader working on development of lasers for industrial applications. His commercial experience covers production engineering and R&D projects in medical devices as well as new startups. In march 2014 he joined LSBC as the Operations Director within Bridge Mentor Project to commercialize Life Science inventions in Poland. He manages the team of commercialization experts and assesses commercial potential of medical devices and technical projects.


Mariusz Jarzebowski

Mariusz Jarzebowski

Entrepreneur who has worked in the high-tech industry in the United States, Austria and Germany. Before coming back to Europe, Mariusz worked in Silicon Valley at NeXT and Apple run by Steve Jobs. In Poland he was involved in establishing and running new ventures. Mariusz worked at a venture capital firm where he continued to be involved in new venture development, and served on the Board of Directors and the Advisory Board. Mariusz helped companies find and enter new markets. At Microsoft, as a specialist in competitive strategy and new markets, he helped organizations create new sources of growth, and learn from start-ups. Helps companies form and launch new ventures. Founder and owner Venture IQ, a technology intelligence firm and Technology Policy Advisor at demosEUROPA–Centre for European Strategy, a think-tank based in Warsaw. Holds MBA and MS degrees from the Warsaw University of Technology Business School in partnership with London Business School. For more, visit www.mariuszjarzebowski.com.


Tomasz Koloszczyk

Tomasz Koloszczyk

Tomasz Koloszczyk. Business Developer and Expert at Orange Poland.

He received M. Sc. degree at Warsaw University of Technology Faculty of Applied Physics and Mathematics and Master’s Certificate in Project Management the George Washington University.

During his professional career he worked for telecom operators, including: PTC (T-Mobile), Telekomunikacja Polska and Orange.

He managed numerous R&D and operational projects related with various ICT domains: IoT/M2M, Smart City, e-Health, Telecommunication networks and Service Platforms, TV and multimedia services. He also coordinated research domains at TP R&D.

He was active in European research initiatives (i.e. Wireless World Initiative) and projects (as WP Leader) as well as standardization bodies (ITU-T).

Currently he is Business Developer responsible for the development of products and services in the domains of IoT / M2M, Telemedicine / e-Health in Orange Poland.

He is also a longtime the European Commission Evaluator and Reviewer (DG Connect).

He is an author of publications related with ICT technologies and services. He gave presentations at various conferences (including ICT-Mobile Summit IST Mobile and Wireless Communications Summit, National Symposium of Telecommunications).


Roland Kozlowski

Roland Kozlowski

Roland Kozlowski received a first class honours degree from the University of Bath and a PhD from the University of Cambridge. He is a bio-entrepreneur who has worked in the industry for over two decades. Roland has held a number of operational roles including Chief Executive Officer of Lectus Therapeutics and Sense Proteomic Limited two venture backed companies which he founded, built and sold. During his career Roland has gained considerable transactional experience ranging from company sale, purchase, financing and in- and out-licensing. In the past Roland ran a Research Groups at the University of Oxford and then University of Bristol where subsequently he was a Visiting Industrial Professor. He has published and patented in the life science field. Roland has served on, or advised, the boards of a number of European companies. He also served on the board of the Bio-Industry Association in the UK. Since 2011 he has been president and owner of Life Science Biznes Consulting (LSBC) a company which specializes in commercializing technology from emerging economies in particular Poland and building business partnerships between Poland and Western Europe. He advises a number of government agencies in Poland on life science investment and commercialisation strategy and is a co-founder and Venture Partner in Life Science Innovations a specialist VC fund based in Poland.  He also sits on the investment committee of Alderley Park Ventures a UK life science VC fund.


Oliver Murphy

Oliver Murphy

Oliver Murphy Partner Transaction Advisory ServicesOliver is a graduate of the University of Manchester in Economics and Government. He speaks fluent Polish. Oliver has a wide range of corporate finance, due diligence and restructuring and integration experience within both the UK and Poland and specialises in cross-border transaction support engagements comprising large multi-disciplinary, multinational teams.


Edyta Niemczyk

Edyta Niemczyk

Edyta Niemczyk graduated from Intercollegiate Faculty of Biotechnology, University of Gdańsk and Medical University of Gdańsk. She received a PhD in molecular biology from Medical University of Gdańsk, supervised by excellent scientist from Nagoya Medical University in Japan – Prof. Takashi Wakabayashi, who was a famous specialist in pathology of mitochondria.

In order to follow the career pathway she envisaged, she applied for the Postdoctoral Research Associate position at the University of Liverpool in UK with the positive outcome. During the two-year contract she was acquainted with Single Nucleotide Polymorphism (SNP) genotyping using Illumina arrays for the purpose of Familiar Pancreatic Cancer investigation. The next step for her career was to participate in the project that would consider SNPs analysis using the most advanced technology and analysis tools. That opportunity was given to her at the University of Birmingham, when she was appointed for the Postdoctoral Fellow position where she was passionately analyzing association of the genetic loci with acute anterior uveitis onset.

Edyta is experienced geneticist perfectly joining the passion for the science and its commercialization. Her key responsibilities at LSBC as the Junior Commercialization Expert are to assess properly the scientific and commercial strengths of analyzed projects.


Martin Oxley

Martin Oxley

Martin Oxley is Country Head of UK Trade and Investment at the British Embassy in Warsaw. Prior to that he was CEO of the BPCC which under his leadership grew to be the leading international business networking organization in Poland. Over the course of the last 15 years he has held CEO and Board positions in the market leading global and regional pharmaceutical companies in Central Europe. He retains a strong interest in healthcare, life sciences and enterprise. He serves on the advisory boards of a number of youth enterprise networks. He is a recognized international expert and speaker on Poland.


Axel Polack

Axel_Polack

Dr. Axel Polack is a General Partner at the “Joint Polish Investment Fund” (www.JPIFund.com), a life science oriented early stage venture capital fund. Before JPIF Dr. Polack was from 2000 to 2014 a key member of the Life Science team at TVM Capital, which raised more than 680m€ in venture capital and accomplished 67 investments, 18 IPOs (“initial public offerings”) and 15 trade sales. Prior to his career in venture capital he was involved in business management as General Manager and basic biomedical research as Deputy Chairman of a large research institute. He has a proven track record in venture capital and early stage company building.

During his time as board member and lead investor representative Genetix Inc. developed into high flying bluebird bio Inc. which attracted 101m$ through an Initial Public Offering (IPO) at NASDAQ in June 2013. Due to break through successes in gene therapy the company reached today a Market Cap of more than 5b$.

As long term board member of Alzheimer’s Disease specialist Probiodrug AG (PBD) was instrumental for the preparation of its IPO on Euronext Amsterdam in October 2014. It represents one of the rare and successful IPOs of German biotech in recent years.


Martin Rand

Martin Rand

Martin Rand is the CEO and co- Founder of VitalFields- a global Farm Management system. Martin has always been passionate about the intersection if agriculture and IT. In 2003 he headed the creation of the first mobile inspecting system for farm compliance inspectors. Martin has also worked in Skype as a Product manager creating simplest and most efficient IP communication software. Simplicity is now the driving factor behind VitalFields which is the simplest crop management system in the world. VitalFields aims to become the largest agricultural consulting platform turning data into valuable insight.


Francesco De Rubertis
 

Francesco De Rubertis

Francesco is a Partner and co-founder of the firm's life sciences practice. He joined Index in 1998 and has overseen all of the life sciences investment of the firm. Present and past Index portfolio companies include: Xo1 (sold to Johnson & Johnson), GlycoVaxyn (sold to GSK), Oncoethix (sold to Merck), Versartis (Nasdaq: VSAR), Egalet (Nasdaq: EGLT), Genmab A/S (Coph: GEN.CO), Molecular Partners A/G (Swx: MOLN), Minerva Neurosciences (Nasdaq: NERV), Aegerion Inc. (Nasdaq: AEGR), Addex Pharmaceuticals SA (Swx: ADXN), PanGenetics B/V (sold to Abbott Pharmaceuticals), Micromet Inc. (sold to Amgen) and Bioxell SpA (sold to Cosmo Pharmaceuticals). Francesco has served on most of these boards.

Prior to joining Index, Francesco was involved in post-doctoral research in genetics at the Whitehead Institute, Massachusetts Institute of Technology (MIT). He is also the author of several publications in international scientific journals. Francesco has a BA in Genetics and Microbiology from the University of Pavia and a PhD in Molecular Biology from the University of Geneva. He is a CFA charter holder, and is a member of the Strategic Advisory Board of the University of Geneva.

Francesco was named by BioWorld as one of 28 "movers and shakers" predicted to shape the biotechnology industry over the next two decades.


Sergiusz Sawin
 

Sergiusz Sawin

Sergiusz Sawin is the co-founder and Chief Innovation Architect at Innovatika – consulting company focused of product and business innovation. His is also a board member of Innovatika Group and Chief Operating Officer at D-Raft S.A. His deep background in innovation stems from his extensive experience working for Kraft Foods Poland (KFP), where he held various positions in finance and marketing and was primarily focused on marketing research, brand & product innovation strategies. During his career at Kraft, he was involved in more than a dozen market innovation projects and gained expertise in different research methodologies. Several of his new product development projects resulted in the launch of innovations that became key products in KFP confectionery portfolio. He also initiated and coordinated international communities of practice related to consumer promotions and brand equity building.

Mr. Sawin has acted as an innovation consultant for numerous clients, including 3M, Polish Telecom, Citibank, Danone, Mepha, Akzo Nobel, Siemens, Mars and Heinz, advising on the development of innovation strategies and innovation campaigns, the improvement of new product development processes, and the introduction of breakthrough products. He was involved in the development of many Innovatika’s products and services including Innovation Springboard, Product Thinkdom, Revenue Generator and Innovation Workout. Mr. Sawin is also an experienced trainer and facilitator: he has run workshop sessions in Europe, USA, Russia and South-East Asia for groups of as many as 300 people. Since 2006 he’s run more than 50 trainings on innovation and business model generation for corporate clients, SMEs and Start-ups helping them in the process of defining their future business models including the Business Model Masterclass program developed by Innovatika in 2013.

Since late 2014 he’s been involved in the development of new business entity – D-Raft corporate accelerator that integrates corporations and startups.

Sergiusz Sawin graduated from the Warsaw School of Economics. He holds two master’s degrees in International Relations and Management & Marketing (with honors). He’s currently working on his PhD on Innovative Business Models.


Andrew Skowronski
 

Andrew Skowronski

Andy Skowronski the author of The Road to Transformation was fortunate to work for one company who embraced Transformational Thinking and change.

"The Road to Transformation" is a Leadership and Change Management program inspired by Andy's time at PepsiCo and Yum! Brands. Its aim is to set organisations and individuals on a path of achieving breakthrough thinking and in turn breakthrough results.

Andy, is an expert with over 25 years industry experience with organisations such as Pepsico, Yum Brands and has worked advising numerous private equity companies around the world. An internationalist who has spent 18 years of his career working abroad, in USA, Poland, the Middle East and in the Far East and has extensive knowledge and connections in these arenas. Andy is an experienced Strategist and Leadership coach, and has been training senior executives for the past 17 years.


Mark Treherne
 

Mark Treherne

Mark has been actively involved in the biopharmaceutical industry for 25 years and was a co-founder and Chief Executive of Cambridge Drug Discovery Limited, leading the Company’s acquisition by BioFocus plc, where he then became a Commercial Director, driving significant growth of its profitable services business. Mark has now served on the Boards of 13 private and public biopharmaceutical companies and is currently on the Boards of Cyclofluidic, Domain Therapeutics, Population Genetics Technologies and Senexis. Dr Treherne has now helped raise more than £140 million for various biopharmaceutical businesses over the last decade. Mark was also formerly Chairman of ERBI Limited, which is a not-for-profit organisation that represents the biotechnology companies based around Cambridge in the East of England. Mark initially trained as a neuroscientist and electrophysiologist at Cambridge University. Mark joined the Life Science Investment Organisation as Chief Executive, following its formation by UK Trade and Investment.


Heiko Visarius
 

Heiko Visarius

Dr. Heiko Visarius is an executive with international experience in the health care sector, especially in the area of medical device technology. A Ph.D. in engineering obtained in the USA and a Swiss/US MBA degree combined with his professional experience allow him to relate to a broad spectrum of business areas, such as sales, marketing, R&D, finance, supply chain and general management. Dr. Heiko Visarius served as CEO of a successful start-up company with an associated exit. Since then, he held various leadership positions with global players of the medical device industry. He had P/L responsibility in Europe for a 3-digit million USD revenue volume in a direct operation. Since 2012, he is owner of VISARTIS Healthcare GmbH. In addition, Dr. Visarius is board member of several Medtech companies as well as an international business school and serves on various expert boards, including Horizon2020 (European Community). He and his family are located in Switzerland.


Felice van Weegen
 

Felice van Weegen

Felice van Weegen joined LSP in 2015. Felice’s responsibility within LSP is to support both private and public investment franchises in all stages of the investment process. Prior to joining LSP, Felice was a consultant at McKinsey & Company where she worked on projects in the Netherlands, UK, Germany, Italy and Nigeria and where she focused on the healthcare and technology sectors. Before she became a consultant, she was a neuroscientist and statistical geneticist, working with the prestigious complex traits genetics group at the Broad Institute and Harvard Medical School in Cambridge, USA where she modeled complex disease genetics using large sequencing datasets. Prior to that, she worked with the department of Biological Psychology at the VU university in Amsterdam to predict heritability of several complex disorders using twin data and where she authored several scientific articles. Felice has a strong scientific background, including a Bachelor’s degree in Biological psychology and a Master’s degree in Neuroscience from the VU university in Amsterdam. She also graduated with an MBA degree from Columbia Business School, New York USA.


Bartosz Walter
 

Bartosz Walter

Bartosz Walter, PhD. Chief Operation Officer in Life Science Innovation Fund (Poland), involved in over 100 projects in last 5 years, investor, former coordinator of national program ‘Design the Future Poland’. For 10 years he worked as a scientist: Regensburg University (PhD), Max Planck Institute (Post-doc), Polish Academy of Sciences (Assistant Professor) and University of California Berkeley (Executive Education). Alumnus of TOP500 innovators (Poland). Awards: Scholarship of Ministry of Science and Sport (Poland), Deutscher Akademischer Austauschdienst (Germany), Tramp Scholarship (Germany).


Joanna Magdalena Zarzynska

Joanna Magdalena Zarzynska

Joanna Magdalena Zarzyńska – VMD, PhD. Graduate of the Faculty of Veterinary Medicine of the University of Warmia and Mazury in Olsztyn and Doctoral Studies at the Faculty of Veterinary Medicine, WULS-SGGW in Warsaw (her doctoral dissertation was awarded by the prestigious Prime Minister Prize). She has obtained a degree in "Management of R & D projects" (postgraduate studies, WSB School of Banking in Gdansk). Since 2006 she works as an assistant professor in the Department of Food Hygiene and Public Health Protection (FVM, WULS-SGGW). She is involved in projects related to dairy production and food safety. Since 2011, she serves in expert board of the National Science Centre. Joanna had participated in numerous training courses in the field of research management of food production sector.

The author or co-author of several scientific publications and over 500 popular publications, including 17 books. Since 2014 Editor in Chief of ZooBiznes magazine.